U.S. FDA Memo Backs Sanofi-Aventis (France) Heart Drug Multaq

WASHINGTON, March 16 (Reuters) - An experimental drug from Sanofi-Aventis should be approved for delaying symptoms of atrial fibrillation and reducing hospitalization, a U.S. drug reviewer said in a memo released on Monday.